(Q50800255)

19 March 2018

title

BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors. (English)

1 reference

19 March 2018

1 reference

1 reference

7

1 reference

19 March 2018

Pierpaolo Maisano Delser

object named as

Pierpaolo Maisano Delser

3

0 references

author name string

Caterina Chianella

1

1 reference

19 March 2018

Daniela Gragnaniello

2

1 reference

19 March 2018

Maria Francesca Visentini

4

1 reference

19 March 2018

Elisabetta Sette

5

1 reference

19 March 2018

Maria Rosaria Tola

6

1 reference

19 March 2018

Silvia Fuselli

8

1 reference

19 March 2018

publication date

1 June 2011

1 reference

19 March 2018

European Journal of Clinical Pharmacology

published in

1 reference

19 March 2018

volume

67

1 reference

19 March 2018

issue

11

1 reference

19 March 2018

page(s)

1147-1157

1 reference

19 March 2018

The cost of dementia in Europe: a review of the evidence, and methodological considerations

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

CYP2D6 genotyping by a multiplex primer extension reaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

TaqMan systems for genotyping of disease-related polymorphisms present in the gene encoding apolipoprotein E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

Butyrylcholinesterase K variant associated with higher enzyme activity in the temporal cortex of elderly patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

Regulation of attention and response to therapy in dementia by butyrylcholinesterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

Clinical pharmacokinetics of galantamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

Molecular diversity at the CYP2D6 locus in the Mediterranean region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1064-X

DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites

21 January 2018

1 reference

12 December 2020

Mini-Mental State Examination: a normative study in Italian elderly population

1 reference

12 December 2020

Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease.

1 reference

12 December 2020

Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease.

1 reference

12 December 2020

Apolipoprotein E: implications for AD neurobiology, epidemiology and risk assessment

1 reference

12 December 2020

American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition

1 reference

12 December 2020

Arlequin (version 3.0): an integrated software package for population genetics data analysis

1 reference

12 December 2020

Assessment of older people: self-maintaining and instrumental activities of daily living

1 reference

12 December 2020

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease

1 reference

12 December 2020

10.1007/S00228-011-1064-X

Identifiers

DOI

1 reference

19 March 2018

1 reference

19 March 2018